Las últimas guías clínicas del American College of Cardiology y la American Heart Association (ACC/AHA), la Canadian Cardiovascular Society (CCS) y el National Institute for Health and Care Excellence (NICE) en el Reino Unido, recomendaban el tratamiento con estatina para 40% a 44% de los individuos de una cohorte contemporánea de atención primaria, según el estudio publicado en el número del 16 de enero de Annals of Internal Medicine.
En cambio, las guías de la European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) recomendaban que solo 15% de la misma cohorte recibiera una estatina. Los investigadores también consideraron una "declaración" de la US Preventive Services Task Force (USPSTF) sobre el uso de estatinas y encontraron que si se aplicaban los criterios de USPSTF, a 31% de la cohorte de prevención primaria se les habría prescrito una estatina.
Estas recomendaciones más conservadoras no estuvieron exentas de consecuencias: utilizando datos observacionales reales sobre eventos y modelación de los eventos con base en las diversas guías, proyectaron que el porcentaje estimado de eventos de aterosclerosis cardiovascular que se podrían haber prevenido con el empleo de estatinas de gran intensidad (suponiendo una reducción de 50% en el colesterol de lipoproteínas de baja densidad) durante 10 años era de 34% con las guías canadiense y estadounidense, 32% con la de NICE, 27% con la de USPSTF y solo 13% con la de ESC/EAS. (Más)
This research clearly demonstrates
that statins do more harm than good
Dr Malcolm Kendrick
They claim the advantages of taking statins for already healthy people are “vanishingly small” and insist diet and exercise deliver far more impressive results in maintaining a healthy heart.
It has also been claimed that “raw data” on the side-effects of the drugs is being withheld.
Statins are taken by six million Britons but remain highly controversial, with many patients complaining of crippling side-effects, while evidence suggests they have no impact on prolonging life.
The medication works to lower the level of cholesterol in the blood and can reduce cardiovascular disease.
In the bombshell review, author Dr Maryanne Demasi said: “Doctors prescribing statins should remain inherently sceptical because the majority of those taking [them] are healthy people at low risk, where the benefits are vanishingly small, and the raw data on side-effects is kept hidden.”
Writing in the British Journal Of Sports Medicine, Dr Demasi has been backed by a coalition of world-leading experts.
She claims statistics are manipulated to exaggerate the benefits of statins and underplay the risks, while dissenting views have been silenced.
Dr Demasi said: “Of utmost importance is that independent researchers are permitted to access the raw data on the side-effects of statins.
“We have learnt from the past, as in the case of Tamiflu, that when drug companies withhold crucial trial data from the public, it perverts the results by favouring the benefits of the drug and underplaying the harms. (Más)
Ver:
Entradas
No hay comentarios:
Publicar un comentario